Academic Journal
Q1Lung Cancer
About Lung Cancer
Lung Cancer is a scholarly journal published by Elsevier Ireland Ltd. SCImago 2025 places it in Q1 with an SJR of 1.928 and an H-index of 160.
Its listed coverage is 1985-2026 and its research categories include Cancer Research (Q1); Oncology (Q1); Pulmonary and Respiratory Medicine (Q1). The 2025 dataset reports 362 documents and 3439 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, Neuroendocrine Tumor Research Advances, Radiomics and Machine Learning in Medical Imaging, Occupational and environmental lung diseases.
Recent Research Articles
Latest publications matched automatically by ISSN.
The efficacy and feasibility of neoadjuvant immunochemotherapy versus chemotherapy in Limited-Stage Small-Cell lung cancer
Yunchu Wei, Ruoyi Jin, Xu Liu, Wenxiang Wang et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109607Standard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC
Takahiro Ando, Koki Fujii, Hiroaki Ikushima, Kousuke Watanabe et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109625The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion
Christoper Hooper, Matthew Anderson, Sarah Bowen Jones, Corinne Faivre-Finn et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109602Discordance in pleural mesothelioma response classification and modelling of impact on clinical trials
Gordon W. Cowell, Joshua Roche, Colin Noble, David B. Stobo et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109624Reassessing surgical resection in small cell lung cancer in the multimodal treatment era
Romina Maria Roesch, Michaela Utz, Florian Eichhorn, Petros Christopoulos et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109600Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study
Jean-Baptiste Assié, Laurent Greillier, Aurelien Gobert, Lionel Falchero et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109622Beyond disease-free survival in adjuvant ALK-targeted therapy: lessons from ELEVATE and ALINA
Lucio Buffoni
2026-11 · DOI: 10.1016/j.lungcan.2026.109608Characterization of the genomic and transcriptomic landscape of invasive non-mucinous lung adenocarcinoma based on IASLC grading
Lu He, Xianfeng Xu, Lingfeng Bi, Chen Ji et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109591Treatment-free interval as a determinant of second-line chemotherapy outcomes in extensive-stage small cell lung cancer: a Dutch population-based study
Anouk H. Eijkelboom, Bas J.M. Peters, Daphne W. Dumoulin, Franz M.N.H. Schramel et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109621Non-small cell lung cancer with synchronous oligometastatic disease at the time of initial diagnosis. Impact of multimodal treatment on prognosis
Christian Schulz, Sarah Swart, Karolina Müller, Denise Bernhardt et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109584Artificial intelligence–based assessment of tumor bed stroma in non–small cell lung cancer after neoadjuvant therapy: Association with pathologic response and survival. A multicenter study
Federica Pezzuto, Luca Vedovelli, Giuseppe Maggioni, Francesco Fortarezza et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109605Artificial Intelligence–Based Assessment of Pathologic Response to Neoadjuvant Chemoimmunotherapy in Non–Small Cell Lung Cancer: An International Multicenter Cohort Study
Daniel Curto, Susana Hernandez, Marta Alonso, Melina Peressini et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109609Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes
Rafael Oliveira, Tarje Halvorsen, Kristin Killingberg, Elisabeth Fritzke Emdal et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109606Change in the incidence of medication-related osteonecrosis of the jaw in lung cancer patients receiving bone modifying agents with immune checkpoint inhibitors
Ayaka Yamada, Hakim Ali Salman, Kaoru Tanaka, Yuko Kinoshita et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109626Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenarios
Dan Zhao, Deyang Xie, Lili Zhang, Nana Zhang et al.
2026-11 · DOI: 10.1016/j.lungcan.2026.109597Utility of artificial intelligence for identifying thoracic lymphadenopathy in lung cancer
Muhiddin Dervis, Anushree Burade, Michael Lanuti, Ibiayi Dagogo-Jack et al.
2026-10 · DOI: 10.1016/j.lungcan.2026.109596Environmental asbestos exposure and lung cancer burden compared with mesothelioma in rural Türkiye: A 33-Year population-based cohort study
Guntulu Ak, Selma Metintas, Nico van Zandwijk, Muzaffer Metintas et al.
2026-10 · DOI: 10.1016/j.lungcan.2026.109592Treatment-stratified associations of pathological complete response with survival in resected limited-stage small cell lung cancer: A multicenter retrospective study with exploratory spatial immune profiling
Zhulin Liu, Yin Zhu, Wanda Bi, Zhaojie Han et al.
2026-10 · DOI: 10.1016/j.lungcan.2026.109579Combined low-dose thoracic computed tomography and circulating tumor cell screening for cancer in ever smokers with peripheral arterial disease: A prospective multicenter cohort study
Alexandra Yannoutsos, Jean Pastre, Diane Damotte, Victor Percheron et al.
2026-10 · DOI: 10.1016/j.lungcan.2026.109587Macroscopic on-site evaluation for stratifying the incremental diagnostic benefit of additional sampling during endobronchial ultrasound-guided transbronchial needle aspiration
Tatsuya Imabayashi, Hiroyuki Hashimoto, Yuki Takahashi, Ikuyo Shionoya et al.
2026-10 · DOI: 10.1016/j.lungcan.2026.109567Reviews
Community Reviews
Version History
September 8, 2026 at 12:04 am
September 8, 2026